nach oben

Diabetologia

Erschienen in:

01.12.2006 | Article

Diabetes mellitus and risk of bladder cancer: a meta-analysis

verfasst von: S. C. Larsson, N. Orsini, K. Brismar, A. Wolk

Erschienen in: Diabetologia | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Epidemiological evidence indicates that individuals with diabetes mellitus have an increased risk of several cancers. We performed a systematic review with meta-analysis to evaluate the association between diabetes and risk of bladder cancer.

Methods

Pertinent studies were identified by searching MEDLINE (from January 1966 to July 2006) and by reviewing the reference lists of retrieved articles. We included case–control and cohort studies reporting relative risk (RR) estimates with 95% CIs (or data to calculate them) of bladder cancer associated with diabetes. Studies of type 1 diabetes were not included. Summary RRs were calculated using a random-effects model.

Results

A total of 16 studies (seven case–control studies, three cohort studies and six cohort studies of diabetic patients) fulfilled the inclusion criteria. Analysis of all studies showed that diabetes was associated with an increased risk of bladder cancer, compared with no diabetes (RR = 1.24, 95% CI 1.08–1.42). There was strong evidence of heterogeneity among these studies (p < 0.0001). Stratification by study design found that diabetes was associated with an increased risk of bladder cancer in case–control studies (RR = 1.37, 95% CI 1.04–1.80, p _{heterogeneity} = 0.005) and cohort studies (RR = 1.43, 95% CI 1.18–1.74, p _{heterogeneity} = 0.17), but not in cohort studies of diabetic patients (RR = 1.01, 95% CI 0.91–1.12, p _{heterogeneity} = 0.35).

Conclusions/interpretation

Findings from this meta-analysis suggest that individuals with diabetes may have a modestly increased risk of bladder cancer.

Nur mit Berechtigung zugänglich

Jemal A, Murray T, Ward E et al (2005) Cancer statistics. CA Cancer J Clin 55:10–30PubMed

Zeegers MP, Tan FE, Dorant E, van Den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89:630–639PubMedCrossRef

Mokdad AH, Ford ES, Bowman BA et al (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76–79PubMedCrossRef

Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273:1605–1609PubMedCrossRef

Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103–111PubMedCrossRef

Anderson KE, Anderson E, Mink PJ et al (2001) Diabetes and endometrial cancer in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 10:611–616PubMed

El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRef

Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

10.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

11.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634

12.

Kabat GC, Dieck GS, Wynder EL (1986) Bladder cancer in nonsmokers. Cancer 57:362–367PubMedCrossRef

13.

Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF Jr (1984) Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119:510–515PubMed

14.

O’Mara BA, Byers T, Schoenfeld E (1985) Diabetes mellitus and cancer risk: a multisite case–control study. J Chronic Dis 38:435–441PubMedCrossRef

15.

Risch HA, Burch JD, Miller AB, Hill GB, Steele R, Howe GR (1988) Dietary factors and the incidence of cancer of the urinary bladder. Am J Epidemiol 127:1179–1191PubMed

16.

La Vecchia C, Negri E, Franceschi S, D’Avanzo B, Boyle P (1994) A case–control study of diabetes mellitus and cancer risk. Br J Cancer 70:950–953PubMed

17.

Kravchick S, Gal R, Cytron S et al (2001) Increased incidence of diabetes mellitus in the patients with transitional cell carcinoma of urinary bladder. Pathol Oncol Res 7:56–59PubMedCrossRef

18.

Ng Y, Husain I, Waterfall N (2003) Diabetes mellitus and bladder cancer—an epidemiological relationship? Pathol Oncol Res 9:30–31PubMedCrossRef

19.

Rousseau MC, Parent ME, Pollak MN, Siemiatycki J (2006) Diabetes mellitus and cancer risk in a population-based case–control study among men from Montreal, Canada. Int J Cancer 118:2105–2109PubMedCrossRef

20.

Tripathi A, Folsom AR, Anderson KE (2002) Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women’s Health Study. Cancer 95:2316–2323PubMedCrossRef

21.

Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef

22.

Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194–202PubMedCrossRef

23.

Kessler II (1970) Cancer mortality among diabetics. J Natl Cancer Inst 44:673–686PubMed

24.

Ragozzino M, Melton LJ 3rd, Chu CP, Palumbo PJ (1982) Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 35:13–19PubMedCrossRef

25.

Adami HO, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314PubMedCrossRef

26.

Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalised with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365PubMedCrossRef

27.

Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26:1047–1951PubMed

28.

Swerdlow AJ, Laing SP, Qiao Z et al (2005) Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 92:2070–2075PubMedCrossRef

29.

Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed

30.

Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE (2005) Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care 28:2501–2507PubMed

31.

Hu F (2006) Diet and lifestyle in prevention and management of type 2 diabetes. In: Mantzoros C (ed) Obesity and diabetes. Humana, Boston, pp 429–443

32.

Møller H, Mellemgaard A, Lindvig K, Olsen JH (1994) Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 30A:344–350PubMedCrossRef

33.

Wolk A, Gridley G, Svensson M et al (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21PubMedCrossRef

34.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRef

35.

Rapp K, Schroeder J, Klenk J et al (2005) Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 93:1062–1067PubMedCrossRef

36.

Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65:311–320PubMed

37.

Bach LA, Rechler MM (1992) Insulin-like growth factors and diabetes. Diabetes Metab Rev 8:229–257PubMedCrossRef

38.

Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109S–3120SPubMed

39.

Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMedCrossRef

40.

Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRef

41.

Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X (2003) Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169:714–717PubMedCrossRef

42.

Dunn SE, Kari FW, French J et al (1997) Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57:4667–4672PubMed

43.

Joshi N, Caputo GM, Weitekamp MR, Karchmer AW (1999) Infections in patients with diabetes mellitus. N Engl J Med 341:1906–1912PubMedCrossRef

Titel: Diabetes mellitus and risk of bladder cancer: a meta-analysis
verfasst von: S. C. Larsson
N. Orsini
K. Brismar
A. Wolk
Publikationsdatum: 01.12.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 12/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0468-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2006

Autocrine insulin action activates Akt and increases survival of isolated human islets

Insulin sensitivity and resistin expression in nitric oxide-deficient rats

The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets

Liver X receptor agonists ameliorate TNFα-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression

Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects